Wockhardt share price
NSE: WOCKPHARMABSE: 532300Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,855.50.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29,276 Cr311th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 71.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 4 May 2026
- 5.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 8.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 7.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 4 May 2026
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,79,19043.6% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 10 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹929 Crdown 3.73%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹107 Crdown 34.76%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 11.5%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
The years either side of a change of basis do not compare. From the year to Mar 2020, the company's revenue for that year, ₹2,844 Cr, differs from its quarters added, ₹3,221 Cr; the company reports a discontinued business.
| ₹ crore | Sep 2024Filed 13 Nov | Dec 2024Filed 7 Feb | Mar 2025Filed 13 Jun | Jun 2025Filed 8 Aug | Sep 2025Filed 3 Nov | Dec 2025Filed 10 Feb | Mar 2026Filed 4 May | Jun 2026Filed 10 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 |
| Net profit | −16 | 20 | −45 | −108 | 82 | 61 | 164 | 107 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | −2.0% | 2.8% | −6.1% | −14.6% | 10.5% | 6.9% | 17.0% | 11.5% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2020: days before it are of the company before the change.PE ratio and valuation history
At or below today's level on 1% of 173 trading days over the last year.
At or below today's level on 92% of 1,732 trading days since Nov 2018.
At or below today's level on 33% of 1,001 trading days over the last 5 years.
At or below today's level on 90% of 2,461 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −17.5% | – | – | 0.0% |
| 3 years | +96.9% | – | – | 0.0% |
| 5 years | +23.2% | −26.7% | +68.1% | 0.0% |
Mutual funds holding it
85 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 52 of the 58 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 23
- CutCut. Funds that held fewer shares than at the end of the month before.
- 35
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 25
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 1
| Fund | |||
|---|---|---|---|
 Tata Small Cap FundTata Mutual Fund | 21,00,000 | 3.36% | ₹444.4 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 11,82,445 | 1.35% | ₹250.2 Cr |
| Tata Large & Mid Cap FundTata Mutual Fund | 9,78,826 | 2.86% | ₹207.1 Cr |
 Invesco India Contra FundInvesco Mutual Fund | 6,57,574 | 0.72% | ₹139.2 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 5,22,354 | 0.31% | ₹110.5 Cr |
| HSBC Flexi Cap FundHSBC Mutual Fund | 3,58,818 | 1.32% | ₹75.9 Cr |
 Bank of India Small Cap FundBank of India Mutual Fund | 3,50,000 | 2.02% | ₹74.1 Cr |
 ITI Small Cap FundITI Mutual Fund | 3,29,595 | 1.90% | ₹69.8 Cr |
 HDFC Large & Mid Cap FundHDFC Mutual Fund | 3,27,653 | 0.24% | ₹69.3 Cr |
| HDFC Manufacturing fundHDFC Mutual Fund | 3,00,000 | 0.62% | ₹63.5 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Wockhardt in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Ajanta PharmaAJANTPHARM | 41,035 | 36.2 | 9.1 | 28.0 | +20.2% | +22.0% | 27.3% | 27.2% | 1.83% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 40,737 | 38.1 | 18.0 | 29.1 | +5.8% | +12.4% | 50.6% | 56.3% | 2.37% |
 Emcure PharmaceuticalsEMCURE | 33,586 | 33.2 | 6.8 | 17.5 | +18.4% | +35.9% | 21.5% | 25.2% | 0.20% |
 Sai Life SciencesSAILIFE | 29,639 | 81.9 | 11.9 | 45.0 | – | – | 15.7% | 18.7% | 0.00% |
 Acutaas ChemicalsACUTAAS | 25,689 | 66.5 | 15.5 | 47.0 | +40.9% | +104.3% | 26.1% | 29.1% | 0.08% |
 Piramal PharmaPPLPHARMA | 25,438 | – | 3.1 | 29.4 | +0.8% | −419.8% | −3.9% | 1.1% | 0.00% |
 Neuland LaboratoriesNEULANDLAB | 24,204 | 48.6 | 12.9 | 31.5 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
 Rubicon ResearchRUBICON | 23,578 | 81.8 | 18.3 | 52.2 | – | – | 22.4% | 25.8% | 0.11% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 17 Nov 2016 | Interim | ₹10.00 |
| 13 Nov 2014 | Interim | ₹20.00 |
| 17 Feb 2014 | Interim | ₹5.00 |
| 7 Nov 2013 | Interim | ₹5.00 |
| 22 Aug 2013 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
| 17 Apr 2008 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.50 |
Latest announcements
Routine notices left out.Share news and announcements
Aug 2026
Wockhardt share price by year
Each calendar year to 2025.Wockhardt share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,446.20 | +2.1% | 1,831.10 | 1,155.50 |
| 2024 | 1,416.85 | +233.9% | 1,531.10 | 422.85 |
| 2023 | 424.35 | +90.2% | 424.35 | 149.30 |
| 2022 | 223.05 | −46.0% | 438.40 | 205.65 |
| 2021 | 412.85 | −24.5% | 786.65 | 390.05 |
| 2020 | 546.55 | +133.6% | 550.50 | 156.20 |
| 2019 | 233.95 | −55.3% | 528.75 | 233.65 |
| 2018 | 523.25 | −43.8% | 992.85 | 446.30 |
| 2017 | 931.35 | +41.6% | 931.35 | 538.05 |
| 2016 | 657.75 | −57.0% | 1,619.35 | 636.20 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,857.00 | 1,864.00 | 1,772.00 | 1,801.70 | 1,803.25 | 8,79,190 | 43.6% |
| 22 Oct 2026 | 1,872.00 | 1,899.90 | 1,846.00 | 1,855.50 | 1,868.97 | 4,57,019 | 31.7% |
| 21 Oct 2026 | 1,920.90 | 1,926.00 | 1,858.00 | 1,877.20 | 1,887.75 | 4,71,545 | 40.2% |
| 19 Oct 2026 | 1,963.70 | 1,966.00 | 1,900.60 | 1,906.30 | 1,926.68 | 3,60,528 | 43.8% |
| 16 Oct 2026 | 1,957.00 | 1,985.50 | 1,941.10 | 1,954.90 | 1,965.40 | 4,48,312 | 42.6% |
| 15 Oct 2026 | 1,988.00 | 1,988.00 | 1,931.20 | 1,949.40 | 1,961.20 | 4,10,296 | 42.9% |
| 14 Oct 2026 | 1,986.00 | 2,003.90 | 1,960.40 | 1,986.10 | 1,984.78 | 4,83,873 | 41.8% |
| 13 Oct 2026 | 1,970.00 | 2,000.20 | 1,901.00 | 1,983.10 | 1,952.03 | 10,01,334 | 32.0% |
| 12 Oct 2026 | 2,002.90 | 2,025.10 | 1,945.60 | 1,963.20 | 1,991.43 | 8,81,944 | 46.1% |
| 9 Oct 2026 | 2,045.80 | 2,064.00 | 1,986.10 | 1,996.40 | 2,010.22 | 6,87,125 | 43.0% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 8 Mar 2022 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 24 Aug 2015 | Price move | – | Between two trading sessions the price moved by a fifth or more. The Nifty 500 moved 5% or more the same way over the same sessions. Not adjusted for. |
| 23 May 2013 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
About Wockhardt
Wockhardt Limited is a pharmaceutical and biotechnology company that researches, makes and sells novel antibiotics, diabetes biosimilars and branded and specialty medicines. A biosimilar is a medicine that is highly similar to an already approved biological drug. The company was incorporated in 1999. Its registered office is in Chhatrapati Sambhajinagar, and its global headquarters is in Mumbai.
The business has three parts: novel antibiotics, biotechnology and pharmaceuticals. The antibiotics side does drug discovery in antimicrobial resistance, which is when bacteria stop responding to existing drugs. Its antibiotics Emrok and Miqnaf are launched in India, and Zaynich has been approved by the US FDA and by India's drug regulator, CDSCO. The biotechnology side focuses its biosimilar programme on diabetes, covering human insulin and insulin analogues. The pharmaceuticals side has a branded and specialty medicines presence across India and global markets.
Wockhardt employs over 3200 people from 27 nationalities and has a presence in the USA, UK, Ireland, Switzerland, Mexico and Russia, among other countries. It has research facilities in India and the UK and a manufacturing facility in Ireland. It reports business from India, the UK, the European Union and the rest of the world, and has 27 overseas subsidiaries, including Wockhardt Bio AG in Switzerland.
In its history, Wockhardt exited its US generics business. Dr. Habil Khorakiwala is its Founder Chairman and is now Executive Chairman. His children Dr. Murtaza Khorakiwala and Dr. Huzaifa Khorakiwala are Managing Director and Executive Director, and Ms. Zahabiya Khorakiwala is a Non-Executive Director.
- Legal name
- Wockhardt Limited
- NSE symbol
- WOCKPHARMA
- BSE code
- 532300
- ISIN
- INE049B01025
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Feb 2000
- Face value
- ₹5
- CIN
- L24230MH1999PLC120720
- Corporate identity number, the registrar of companies' code for it